TECX
Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.76
+2.79%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -32.4%
- EBIT
- -27.8%
- EPS
- -13.1%
- Free cash flow
- -12.4%
- Operating cash flow
- -12.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -16.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.1%
- EBIT
- -44.9%
- Net income
- -27.9%
- EPS
- -3.1%
- Free cash flow
- -1.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026